A Phase 1/2 Trial of ADI-212 in mCRPC
This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metastatic castration-resistant prostate cancer (mCRPC)
Histologic and/or cytologic confirmation of adenocarcinoma of the prostate [+14]
Prior radiation therapy within 21 days prior to start of study treatment [+12]